{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T09:55:30Z","timestamp":1791453330747,"version":"4.3.3"},"reference-count":215,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T00:00:00Z","timestamp":1562716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Innate immunity represents the semi-specific first line of defense and provides the initial host response to tissue injury, trauma, and pathogens. Innate immunity activates the adaptive immunity, and both act highly regulated together to establish and maintain tissue homeostasis. Any dysregulation of this interaction can result in chronic inflammation and autoimmunity and is thought to be a major underlying cause in the initiation and progression of highly prevalent immune-mediated inflammatory diseases (IMIDs) such as psoriasis, rheumatoid arthritis, inflammatory bowel diseases among others, and periodontitis. Th1 and Th2 cells of the adaptive immune system are the major players in the pathogenesis of IMIDs. In addition, Th17 cells, their key cytokine IL-17, and IL-23 seem to play pivotal roles. This review aims to provide an overview of the current knowledge about the differentiation of Th17 cells and the role of the IL-17\/IL-23 axis in the pathogenesis of IMIDs. Moreover, it aims to review the association of these IMIDs with periodontitis and briefly discusses the therapeutic potential of agents that modulate the IL-17\/IL-23 axis.<\/jats:p>","DOI":"10.3390\/ijms20143394","type":"journal-article","created":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T11:56:51Z","timestamp":1562759811000},"page":"3394","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":455,"title":["Th17 Cells and the IL-23\/IL-17 Axis in the Pathogenesis of Periodontitis and Immune-Mediated Inflammatory Diseases"],"prefix":"10.3390","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9337-5279","authenticated-orcid":false,"given":"K\u00fcbra","family":"Kaymaz","sequence":"first","affiliation":[{"name":"Department of Periodontics, Preventive and Restorative Dentistry, University Medical Centre Hamburg-Eppendorf, 20246 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Beikler","sequence":"additional","affiliation":[{"name":"Department of Periodontics, Preventive and Restorative Dentistry, University Medical Centre Hamburg-Eppendorf, 20246 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,7,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/imm.12597","article-title":"Innate immunity in vertebrates: An overview","volume":"148","year":"2016","journal-title":"Immunology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.it.2007.08.004","article-title":"Inside, outside, upside down: Damage-associated molecular-pattern molecules (DAMPs) and redox","volume":"28","author":"Rubartelli","year":"2007","journal-title":"Trends Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"7461","DOI":"10.1073\/pnas.131202998","article-title":"How the immune system works to protect the host from infection: A personal view","volume":"98","author":"Janeway","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1042\/EBC20160017","article-title":"The immune system","volume":"60","author":"Nicholson","year":"2016","journal-title":"Essays Biochem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"d12","DOI":"10.2741\/A171","article-title":"Cytokines in acute and chronic inflammation","volume":"2","author":"Feghali","year":"1997","journal-title":"Front. Biosci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1136\/pgmj.2006.052688","article-title":"Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: A medical revolution","volume":"83","author":"Kuek","year":"2007","journal-title":"Postgrad. Med. J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clim.2014.05.004","article-title":"Emerging role of IL-17 and Th17 cells in systemic lupus erythematosus","volume":"154","author":"Martin","year":"2014","journal-title":"Clin. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jaut.2018.01.001","article-title":"Th17cells, gammadelta T cells and their interplay in EAE and multiple sclerosis","volume":"87","author":"McGinley","year":"2018","journal-title":"J. Autoimmun."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1600-0757.2010.00360.x","article-title":"Oral biofilm-associated diseases: Trends and implications for quality of life, systemic health and expenditures","volume":"55","author":"Beikler","year":"2011","journal-title":"Periodontology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1600-0757.2009.00326.x","article-title":"Epidemiologic patterns of chronic and aggressive periodontitis","volume":"53","author":"Demmer","year":"2010","journal-title":"Periodontology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/prd.12002","article-title":"Inflammatory and immune pathways in the pathogenesis of periodontal disease","volume":"64","author":"Cekici","year":"2014","journal-title":"Periodontology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"ii30","DOI":"10.1136\/ard.2004.031120","article-title":"Psoriasis pathophysiology: Current concepts of pathogenesis","volume":"64","author":"Krueger","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.jaad.2012.04.039","article-title":"The association of psoriasis with autoimmune diseases","volume":"67","author":"Wu","year":"2012","journal-title":"J. Am. Acad. Derm."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2405291","DOI":"10.1155\/2017\/2405291","article-title":"Cytokine Imbalance as a Common Mechanism in Both Psoriasis and Rheumatoid Arthritis","volume":"2017","author":"Tan","year":"2017","journal-title":"Mediat. Inflamm."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"116","DOI":"10.4103\/jisp.jisp_362_17","article-title":"Comparison of serum tumor necrosis factor-alpha levels in rheumatoid arthritis individuals with and without chronic periodontitis: A biochemical study","volume":"22","author":"Thilagar","year":"2018","journal-title":"J. Indian Soc. Periodontol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/intimm\/dxw006","article-title":"CD4+ T-cell subsets in inflammatory diseases: Beyond the Th1\/Th2 paradigm","volume":"28","author":"Hirahara","year":"2016","journal-title":"Int. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1146\/annurev-immunol-030409-101212","article-title":"Differentiation of effector CD4 T cell populations","volume":"28","author":"Zhu","year":"2010","journal-title":"Annu. Rev. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S1081-1206(10)62426-X","article-title":"T-cell subsets (Th1 versus Th2)","volume":"85","author":"Romagnani","year":"2000","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00054725-199911000-00009","article-title":"Th1\/Th2 cells","volume":"5","author":"Romagnani","year":"1999","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/nature01355","article-title":"Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain","volume":"421","author":"Cua","year":"2003","journal-title":"Nature"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1084\/jem.192.1.123","article-title":"Failure to suppress the expansion of the activated CD4 T cell population in interferon gamma-deficient mice leads to exacerbation of experimental autoimmune encephalomyelitis","volume":"192","author":"Chu","year":"2000","journal-title":"J. Exp. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4049\/jimmunol.156.1.5","article-title":"Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE)","volume":"156","author":"Ferber","year":"1996","journal-title":"J. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.4049\/jimmunol.170.4.2153","article-title":"Induction of experimental autoimmune encephalomyelitis in IL-12 receptor-beta 2-deficient mice: IL-12 responsiveness is not required in the pathogenesis of inflammatory demyelination in the central nervous system","volume":"170","author":"Zhang","year":"2003","journal-title":"J. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S1074-7613(00)00070-4","article-title":"Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12","volume":"13","author":"Oppmann","year":"2000","journal-title":"Immunity"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1084\/jem.20041257","article-title":"IL-23 drives a pathogenic T cell population that induces autoimmune inflammation","volume":"201","author":"Langrish","year":"2005","journal-title":"J. Exp. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1084\/jem.20030896","article-title":"Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation","volume":"198","author":"Murphy","year":"2003","journal-title":"J. Exp. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/ni1254","article-title":"Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages","volume":"6","author":"Harrington","year":"2005","journal-title":"Nat. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/978-94-017-9487-9_2","article-title":"TH1\/TH2 cell differentiation and molecular signals","volume":"841","author":"Zhang","year":"2014","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.immuni.2010.06.011","article-title":"Genome-wide profiling of interleukin-4 and STAT6 transcription factor regulation of human Th2 cell programming","volume":"32","author":"Elo","year":"2010","journal-title":"Immunity"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1177\/154405910808700908","article-title":"A new inflammatory cytokine on the block: Re-thinking periodontal disease and the Th1\/Th2 paradigm in the context of Th17 cells and IL-17","volume":"87","author":"Gaffen","year":"2008","journal-title":"J. Dent. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.tips.2014.07.006","article-title":"Targeting Th17 cells in autoimmune diseases","volume":"35","author":"Yang","year":"2014","journal-title":"Trends Pharm. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Fasching, P., Stradner, M., Graninger, W., Dejaco, C., and Fessler, J. (2017). Therapeutic Potential of Targeting the Th17\/Treg Axis in Autoimmune Disorders. Molecules, 22.","DOI":"10.3390\/molecules22010134"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.immuni.2006.01.001","article-title":"TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells","volume":"24","author":"Veldhoen","year":"2006","journal-title":"Immunity"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"17003","DOI":"10.1074\/jbc.M801286200","article-title":"Foxp3 inhibits RORgammat-mediated IL-17A mRNA transcription through direct interaction with RORgammat","volume":"283","author":"Ichiyama","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"203705","DOI":"10.1155\/2013\/203705","article-title":"Th17 and Treg cells in bone related diseases","volume":"2013","author":"Wang","year":"2013","journal-title":"Clin. Dev. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1074\/jbc.M308809200","article-title":"Functional cooperation between interleukin-17 and tumor necrosis factor-alpha is mediated by CCAAT\/enhancer-binding protein family members","volume":"279","author":"Ruddy","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3389\/fgene.2015.00236","article-title":"Regulation of IL-17 in autoimmune diseases by transcriptional factors and microRNAs","volume":"6","author":"Khan","year":"2015","journal-title":"Front. Genet."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.immuni.2007.11.016","article-title":"T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma","volume":"28","author":"Yang","year":"2008","journal-title":"Immunity"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/jdv.14868","article-title":"Shifting the focus\u2014the primary role of IL-23 in psoriasis and other inflammatory disorders","volume":"32","author":"Gooderham","year":"2018","journal-title":"J. Eur. Acad. Derm. Venereol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1172\/JCI28508","article-title":"The IL-23\/IL-17 axis in inflammation","volume":"116","author":"Iwakura","year":"2006","journal-title":"J. Clin. Investig."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nature05970","article-title":"IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells","volume":"448","author":"Korn","year":"2007","journal-title":"Nature"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.cell.2012.09.016","article-title":"A validated regulatory network for Th17 cell specification","volume":"151","author":"Ciofani","year":"2012","journal-title":"Cell"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"205156","DOI":"10.1155\/2015\/205156","article-title":"Harnessing the Therapeutic Potential of Th17 Cells","volume":"2015","author":"Bystrom","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/ni1500","article-title":"The development of inflammatory T(H)-17 cells requires interferon-regulatory factor 4","volume":"8","author":"Brustle","year":"2007","journal-title":"Nat. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.cell.2006.07.035","article-title":"The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells","volume":"126","author":"Ivanov","year":"2006","journal-title":"Cell"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"104ra100","DOI":"10.1126\/scitranslmed.3002949","article-title":"Human TH17 cells are long-lived effector memory cells","volume":"3","author":"Kryczek","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Guo, B. (2016). IL-10 Modulates Th17 Pathogenicity during Autoimmune Diseases. J. Clin. Cell. Immunol., 7.","DOI":"10.4172\/2155-9899.1000400"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/ni1539","article-title":"TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology","volume":"8","author":"McGeachy","year":"2007","journal-title":"Nat. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni.2416","article-title":"Induction and molecular signature of pathogenic TH17 cells","volume":"13","author":"Lee","year":"2012","journal-title":"Nat. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/ni.1993","article-title":"Fate mapping of IL-17-producing T cells in inflammatory responses","volume":"12","author":"Hirota","year":"2011","journal-title":"Nat. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/ni.3742","article-title":"Interleukin 17 is a chief orchestrator of immunity","volume":"18","author":"Veldhoen","year":"2017","journal-title":"Nat. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/prd.12083","article-title":"Basic biology and role of interleukin-17 in immunity and inflammation","volume":"69","author":"Zenobia","year":"2015","journal-title":"Periodontology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.4049\/jimmunol.1102576","article-title":"Life before seventeen: Cloning of the IL-17 receptor","volume":"187","author":"Gaffen","year":"2011","journal-title":"J. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1365-2567.2011.03465.x","article-title":"The interleukin-17 cytokine family: Critical players in host defence and inflammatory diseases","volume":"134","author":"Pappu","year":"2011","journal-title":"Immunology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/ca.22980","article-title":"Rheumatoid arthritis in review: Clinical, anatomical, cellular and molecular points of view","volume":"31","author":"Sharif","year":"2018","journal-title":"Clin. Anat."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0001-7310(14)70015-8","article-title":"IL-17 and IL-17R: An auspicious therapeutic target for psoriatic disease","volume":"105","author":"Mitra","year":"2014","journal-title":"Actas Dermosifiliogr."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1080\/08830185.2016.1269175","article-title":"Fibroblast-like synoviocytes-dependent effector molecules as a critical mediator for rheumatoid arthritis: Current status and future directions","volume":"36","author":"Ganesan","year":"2017","journal-title":"Int. Rev. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/1348-0421.12560","article-title":"Interleukin-17 family cytokines in protective immunity against infections: Role of hematopoietic cell-derived and non-hematopoietic cell-derived interleukin-17s","volume":"62","author":"Matsuzaki","year":"2018","journal-title":"Microbiol. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/odi.12598","article-title":"IL-17: Overview and role in oral immunity and microbiome","volume":"23","author":"Abusleme","year":"2017","journal-title":"Oral Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"986789","DOI":"10.1155\/2013\/986789","article-title":"Th17 cells in immunity and autoimmunity","volume":"2013","author":"Bedoya","year":"2013","journal-title":"Clin. Dev. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"ftw111","DOI":"10.1093\/femspd\/ftw111","article-title":"Cytokines IL-17 and IL-22 in the host response to infection","volume":"74","author":"Valeri","year":"2016","journal-title":"Pathog. Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1084\/jem.194.4.519","article-title":"Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense","volume":"194","author":"Ye","year":"2001","journal-title":"J. Exp. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0001-7310(14)70016-X","article-title":"IL-17 and infections","volume":"105","author":"Ling","year":"2014","journal-title":"Actas Dermosifiliogr."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/bjd.15015","article-title":"Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management","volume":"177","author":"Saunte","year":"2017","journal-title":"Br. J. Derm."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/rheumatology\/keu172","article-title":"Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: A systematic review and meta-analysis of randomized controlled trials and long-term extension studies","volume":"53","author":"Souto","year":"2014","journal-title":"Rheumatology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.immuni.2016.12.010","article-title":"On-going Mechanical Damage from Mastication Drives Homeostatic Th17 Cell Responses at the Oral Barrier","volume":"46","author":"Dutzan","year":"2017","journal-title":"Immunity"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1182\/blood-2005-09-010116","article-title":"An essential role for IL-17 in preventing pathogen-initiated bone destruction: Recruitment of neutrophils to inflamed bone requires IL-17 receptor-dependent signals","volume":"109","author":"Yu","year":"2007","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00011-014-0776-7","article-title":"Clinical associations between IL-17 family cytokines and periodontitis and potential differential roles for IL-17A and IL-17E in periodontal immunity","volume":"63","author":"Awang","year":"2014","journal-title":"Inflamm. Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1399-302X.2005.00241.x","article-title":"Gene expression analysis of the CD4+ T-cell clones derived from gingival tissues of periodontitis patients","volume":"20","author":"Ito","year":"2005","journal-title":"Oral Microbiol Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/jcpe.12238","article-title":"The presence, function and regulation of IL-17 and Th17 cells in periodontitis","volume":"41","author":"Cheng","year":"2014","journal-title":"J. Clin. Periodontol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1399-302X.2008.00463.x","article-title":"Evidence of the presence of T helper type 17 cells in chronic lesions of human periodontal disease","volume":"24","author":"Cardoso","year":"2009","journal-title":"Oral Microbiol. Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1600-051X.2005.00684.x","article-title":"Levels of interleukin-17 in gingival crevicular fluid and in supernatants of cellular cultures of gingival tissue from patients with chronic periodontitis","volume":"32","author":"Vernal","year":"2005","journal-title":"J. Clin. Periodontol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1600-0765.2011.01464.x","article-title":"Signs of the presence of Th17 cells in chronic periodontal disease","volume":"47","author":"Adibrad","year":"2012","journal-title":"J. Periodontal Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1177\/0022034510369297","article-title":"IL-17 in sera from patients with aggressive periodontitis","volume":"89","author":"Schenkein","year":"2010","journal-title":"J. Dent. Res."},{"key":"ref_75","first-page":"23","article-title":"Expression levels of th-2 and th-17 characteristic genes in healthy tissue versus periodontitis","volume":"10","author":"Behfarnia","year":"2013","journal-title":"J. Dent."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/imm.12891","article-title":"Autoimmunity and autoimmune co-morbidities in psoriasis","volume":"154","author":"Furue","year":"2018","journal-title":"Immunology"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.autrev.2014.01.008","article-title":"Diagnosis and classification of psoriasis","volume":"13","author":"Raychaudhuri","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and comorbid diseases: Epidemiology","volume":"76","author":"Takeshita","year":"2017","journal-title":"J. Am. Acad. Derm."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.ajhg.2015.10.019","article-title":"Genome-wide association analysis of psoriatic arthritis and cutaneous psoriasis reveals differences in their genetic architecture","volume":"97","author":"Stuart","year":"2015","journal-title":"Am. J. Hum. Genet."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/jid.2011.364","article-title":"A role for epigenetics in psoriasis: Methylated Cytosine-Guanine sites differentiate lesional from nonlesional skin and from normal skin","volume":"132","author":"Gudjonsson","year":"2012","journal-title":"J. Investig. Derm."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"22962","DOI":"10.3402\/jom.v6.22962","article-title":"Genetic dysbiosis: The role of microbial insults in chronic inflammatory diseases","volume":"6","author":"Nibali","year":"2014","journal-title":"J. Oral Microbiol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/exd.12572","article-title":"Psoriasis is not an autoimmune disease?","volume":"24","author":"Fry","year":"2015","journal-title":"Exp. Derm."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/BOR.0000000000000147","article-title":"Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis","volume":"27","author":"Mease","year":"2015","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/ced.12845","article-title":"Circulating T-helper 17 cells and associated cytokines in psoriasis","volume":"41","author":"Chhabra","year":"2016","journal-title":"Clin. Exp. Derm."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s10067-015-2961-7","article-title":"Role of IL-17 in the pathogenesis of psoriatic arthritis and axial spondyloarthritis","volume":"34","author":"Raychaudhuri","year":"2015","journal-title":"Clin. Rheumatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/jid.2009.59","article-title":"The IL-23\/Th17 axis in the immunopathogenesis of psoriasis","volume":"129","author":"Nestle","year":"2009","journal-title":"J. Investig. Derm."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cytogfr.2014.10.009","article-title":"An inflammatory triangle in psoriasis: TNF, type I IFNs and IL-17","volume":"26","author":"Grine","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.jid.2019.01.014","article-title":"IL-17 and IL-22 promote keratinocyte stemness in the germinative compartment in psoriasis","volume":"139","author":"Ekman","year":"2019","journal-title":"J. Investig. Derm."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"409","DOI":"10.4049\/jimmunol.161.1.409","article-title":"Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines","volume":"161","author":"Chabaud","year":"1998","journal-title":"J. Immunol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1177\/0022034518805739","article-title":"The Oral Microbiota Is Modified by Systemic Diseases","volume":"98","author":"Graves","year":"2019","journal-title":"J. Dent. Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.micpath.2015.09.003","article-title":"Role of bacteria in leukocyte adhesion deficiency-associated periodontitis","volume":"94","author":"Hajishengallis","year":"2016","journal-title":"Microb. Pathog."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"229ra40","DOI":"10.1126\/scitranslmed.3007696","article-title":"Defective neutrophil recruitment in leukocyte adhesion deficiency type I disease causes local IL-17-driven inflammatory bone loss","volume":"6","author":"Moutsopoulos","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1586\/1744666X.2014.929944","article-title":"Etiology of leukocyte adhesion deficiency-associated periodontitis revisited: Not a raging infection but a raging inflammatory response","volume":"10","author":"Hajishengallis","year":"2014","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_95","first-page":"e4064","article-title":"Increased risk of periodontitis in patients with psoriatic disease: A nationwide population-based retrospective cohort study","volume":"5","author":"Su","year":"2017","journal-title":"PeerJ"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/JPER.18-0394","article-title":"Periodontitis as another comorbidity associated with psoriasis: A case-control study","volume":"90","author":"Mendes","year":"2018","journal-title":"J. Periodontol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/j.1468-3083.2012.04615.x","article-title":"Association of chronic plaque psoriasis and severe periodontitis: A hospital based case-control study","volume":"27","author":"Lazaridou","year":"2013","journal-title":"J. Eur. Acad. Derm. Venereol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1111\/j.1365-2133.2012.11126.x","article-title":"The effects of chronic periodontitis and its treatment on the subsequent risk of psoriasis","volume":"167","author":"Keller","year":"2012","journal-title":"Br. J. Derm."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/jdv.13814","article-title":"Risk of periodontitis in patients with psoriasis and psoriatic arthritis","volume":"31","author":"Egeberg","year":"2017","journal-title":"J. Eur. Acad. Derm. Venereol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/odi.12271","article-title":"Association of chronic periodontitis and psoriasis: Periodontal status with severity of psoriasis","volume":"21","author":"Sharma","year":"2015","journal-title":"Oral Dis."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"119","DOI":"10.33891\/FSZ.109.4.119-124","article-title":"Smoking and Psoriasis as Synergistic Risk Factors in Periodontal disease","volume":"109","author":"Gheorghita","year":"2016","journal-title":"Fogorv. Szle."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Antal, M., Braunitzer, G., Mattheos, N., Gyulai, R., and Nagy, K. (2014). Smoking as a permissive factor of periodontal disease in psoriasis. PloS ONE, 9.","DOI":"10.1371\/journal.pone.0092333"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1136\/ard.2006.054924","article-title":"Proteomic analysis of secreted proteins in early rheumatoid arthritis: Anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines","volume":"66","author":"Hueber","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nrrheum.2012.237","article-title":"Genetics and epigenetics of rheumatoid arthritis","volume":"9","author":"Viatte","year":"2013","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41413-018-0016-9","article-title":"Rheumatoid arthritis: Pathological mechanisms and modern pharmacologic therapies","volume":"6","author":"Guo","year":"2018","journal-title":"Bone Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s00281-017-0633-1","article-title":"Cellular and molecular perspectives in rheumatoid arthritis","volume":"39","author":"Veale","year":"2017","journal-title":"Semin. Immunopathol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.immuni.2017.02.006","article-title":"Immunopathogenesis of Rheumatoid Arthritis","volume":"46","author":"Firestein","year":"2017","journal-title":"Immunity"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1084\/jem.20071397","article-title":"Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model","volume":"204","author":"Hirota","year":"2007","journal-title":"J. Exp. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/BF02684010","article-title":"Overexpression of IL-17 in the knee joint of collagen type II immunized mice promotes collagen arthritis and aggravates joint destruction","volume":"51","author":"Lubberts","year":"2002","journal-title":"Inflamm. Res."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"6173","DOI":"10.4049\/jimmunol.171.11.6173","article-title":"Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice","volume":"171","author":"Nakae","year":"2003","journal-title":"J. Immunol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1084\/jem.20062259","article-title":"T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis","volume":"204","author":"Hirota","year":"2007","journal-title":"J. Exp. Med."},{"key":"ref_112","first-page":"539","article-title":"The Role of IL-17 in the Human Immune System and Its Blockage as a Treatment of Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis","volume":"17","author":"Jaller","year":"2018","journal-title":"J. Drugs Derm."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1084\/jem.20061775","article-title":"Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction","volume":"203","author":"Sato","year":"2006","journal-title":"J. Exp. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/gtc.12039","article-title":"Recent advances in understanding the molecular mechanisms of the development and function of Th17 cells","volume":"18","author":"Kurebayashi","year":"2013","journal-title":"Genes Cells"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1177\/154405910708600409","article-title":"MMPs, IL-1, and TNF are regulated by IL-17 in periodontitis","volume":"86","author":"Beklen","year":"2007","journal-title":"J. Dent. Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1600-051X.2009.01390.x","article-title":"Over-expression of forkhead box P3 and its association with receptor activator of nuclear factor-kappa B ligand, interleukin (IL)-17, IL-10 and transforming growth factor-beta during the progression of chronic periodontitis","volume":"36","author":"Dutzan","year":"2009","journal-title":"J. Clin. Periodontol."},{"key":"ref_117","first-page":"472","article-title":"IL-17 regulates the expressions of RANKL and OPG in human periodontal ligament cells via TRAF6\/TBK1-JNK\/NF-kappaB pathways","volume":"3","author":"Lin","year":"2014","journal-title":"Immunology"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1136\/annrheumdis-2012-202373","article-title":"IL-17\/Th17 mediated synovial inflammation is IL-22 independent","volume":"72","author":"Corneth","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.3389\/fimmu.2018.02901","article-title":"Th22 Cells Promote Osteoclast Differentiation via Production of IL-22 in Rheumatoid Arthritis","volume":"9","author":"Miyazaki","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/jre.12461","article-title":"Increased levels of the T-helper 22-associated cytokine (interleukin-22) and transcription factor (aryl hydrocarbon receptor) in patients with periodontitis are associated with osteoclast resorptive activity and severity of the disease","volume":"52","author":"Rojas","year":"2017","journal-title":"J. Periodontal Res."},{"key":"ref_121","first-page":"70","article-title":"Association of periodontal disease and tooth loss with rheumatoid arthritis in the US population","volume":"35","author":"Dietrich","year":"2008","journal-title":"J. Rheumatol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1902\/jop.2013.120595","article-title":"Gingival crevicular fluid, serum levels of receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-17 in patients with rheumatoid arthritis and osteoporosis and with periodontal disease","volume":"84","author":"Gumus","year":"2013","journal-title":"J. Periodontol."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Correa, M.G., Sacchetti, S.B., Ribeiro, F.V., Pimentel, S.P., Casarin, R.C., Cirano, F.R., and Casati, M.Z. (2017). Periodontitis increases rheumatic factor serum levels and citrullinated proteins in gingival tissues and alter cytokine balance in arthritic rats. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0174442"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"666","DOI":"10.4103\/0972-124X.142470","article-title":"Autoimmune correlation of rheumatoid arthritis and periodontitis","volume":"18","author":"Arunachalam","year":"2014","journal-title":"J. Indian Soc. Periodontol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.intimp.2008.09.008","article-title":"Antibody responses to Porphyromonas gingivalis (P. gingivalis) in subjects with rheumatoid arthritis and periodontitis","volume":"9","author":"Mikuls","year":"2009","journal-title":"Int. Immunopharmacol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(12)60150-0","article-title":"Ulcerative colitis","volume":"380","author":"Ordas","year":"2012","journal-title":"Lancet"},{"key":"ref_127","first-page":"699","article-title":"Ulcerative colitis","volume":"87","author":"Adams","year":"2013","journal-title":"Am. Fam. Physician"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0140-6736(12)60026-9","article-title":"Crohn\u2019s disease","volume":"380","author":"Baumgart","year":"2012","journal-title":"Lancet"},{"key":"ref_129","first-page":"1","article-title":"Current clinical issue of skin lesions in patients with inflammatory bowel disease","volume":"5","author":"Iida","year":"2019","journal-title":"Clin. J. Gastroenterol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3748\/wjg.v20.i1.91","article-title":"Inflammatory bowel disease: Pathogenesis","volume":"20","author":"Zhang","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_131","first-page":"253","article-title":"Role of the IL-23\/IL-17 axis in Crohn\u2019s disease","volume":"14","author":"Siakavellas","year":"2012","journal-title":"Discov. Med."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1136\/gut.2007.135053","article-title":"IL23 differentially regulates the Th1\/Th17 balance in ulcerative colitis and Crohn\u2019s disease","volume":"57","author":"Kobayashi","year":"2008","journal-title":"Gut"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.clim.2003.09.013","article-title":"Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice","volume":"110","author":"Ogawa","year":"2004","journal-title":"Clin. Immunol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.bbrc.2008.09.019","article-title":"Involvement of IL-17A in the pathogenesis of DSS-induced colitis in mice","volume":"377","author":"Ito","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1365-2249.2010.04093.x","article-title":"The increased mucosal mRNA expressions of complement C3 and interleukin-17 in inflammatory bowel disease","volume":"160","author":"Sugihara","year":"2010","journal-title":"Clin. Exp. Immunol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"425915","DOI":"10.1155\/2013\/425915","article-title":"High intestinal and systemic levels of interleukin-23\/T-helper 17 pathway in Chinese patients with inflammatory bowel disease","volume":"2013","author":"Song","year":"2013","journal-title":"Mediat. Inflamm."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/gut.52.1.65","article-title":"Increased expression of interleukin 17 in inflammatory bowel disease","volume":"52","author":"Fujino","year":"2003","journal-title":"Gut"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/ibd.20339","article-title":"Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): Upregulated colonic IL-17F expression in active Crohn\u2019s disease and analysis of the IL17F p.His161Arg polymorphism in IBD","volume":"14","author":"Seiderer","year":"2008","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_139","first-page":"1381","article-title":"Oral manifestations of systemic disease","volume":"82","author":"Chi","year":"2010","journal-title":"Am. Fam. Physician"},{"key":"ref_140","first-page":"e934","article-title":"Oral manifestations as the first presenting sign of Crohn\u2019s disease in a pediatric patient","volume":"9","author":"Eckel","year":"2017","journal-title":"J. Clin. Exp. Dent."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/sj.bdj.2016.954","article-title":"Gastrointestinal diseases and their oro-dental manifestations: Part 1: Crohn\u2019s disease","volume":"221","author":"Tan","year":"2016","journal-title":"Br. Dent. J."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.mayocp.2017.04.010","article-title":"Crohn Disease: epidemiology, diagnosis, and management","volume":"92","author":"Feuerstein","year":"2017","journal-title":"Mayo Clin. Proc."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1600-051X.2008.01231.x","article-title":"Prevalence of periodontitis and DMFT index in patients with Crohn\u2019s disease and ulcerative colitis","volume":"35","author":"Brito","year":"2008","journal-title":"J. Clin. Periodontol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s00384-018-3117-4","article-title":"Increased risk of periodontitis among patients with Crohn\u2019s disease: A population-based matched-cohort study","volume":"33","author":"Chi","year":"2018","journal-title":"Int. J. Colorectal Dis."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/jcpe.12698","article-title":"Inflammatory bowel disease and oral health: Systematic review and a meta-analysis","volume":"44","author":"Papageorgiou","year":"2017","journal-title":"J. Clin. Periodontol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"7963","DOI":"10.3748\/wjg.v22.i35.7963","article-title":"Periodontal and inflammatory bowel diseases: Is there evidence of complex pathogenic interactions?","volume":"22","author":"Figueredo","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0140-6736(05)66990-5","article-title":"Sjogren\u2019s syndrome","volume":"366","author":"Fox","year":"2005","journal-title":"Lancet"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/BOR.0000000000000096","article-title":"Advances in the understanding and treatment of systemic complications in Sjogren\u2019s syndrome","volume":"26","year":"2014","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_149","unstructured":"Carsons, S.E., and Patel, B.C. (2019). Sjogren Syndrome. StatPearls, StatPearls Publishing LLC."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1177\/0961203318801673","article-title":"Primary Sjogren\u2019s syndrome","volume":"27","author":"Bowman","year":"2018","journal-title":"Lupus"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2174\/1573397113666170125122858","article-title":"Unique Phenotypes and Functions of Follicular Helper T Cells and Regulatory T Cells in Sjogren\u2019s Syndrome","volume":"14","author":"Saito","year":"2018","journal-title":"Curr. Rheumatol. Rev."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1586\/1744666X.2014.878650","article-title":"Dendritic cells, T-cells and epithelial cells: A crucial interplay in immunopathology of primary Sjogren\u2019s syndrome","volume":"10","author":"Hillen","year":"2014","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Matsui, K., and Sano, H. (2017). T Helper 17 Cells in Primary Sjogren\u2019s Syndrome. J. Clin. Med.","DOI":"10.3390\/jcm6070065"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/ni.3554","article-title":"TFH cells progressively differentiate to regulate the germinal center response","volume":"17","author":"Weinstein","year":"2016","journal-title":"Nat. Immunol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.2353\/ajpath.2009.090319","article-title":"Systemic and local interleukin-17 and linked cytokines associated with Sjogren\u2019s syndrome immunopathogenesis","volume":"175","author":"Katsifis","year":"2009","journal-title":"Am. J. Pathol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"R64","DOI":"10.1186\/ar3780","article-title":"TLR2 ligation induces the production of IL-23\/IL-17 via IL-6, STAT3 and NF-kB pathway in patients with primary Sjogren\u2019s syndrome","volume":"14","author":"Kwok","year":"2012","journal-title":"Arthritis Res."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1136\/annrheumdis-2013-203447","article-title":"Predominantly proinflammatory cytokines decrease after B cell depletion therapy in patients with primary Sjogren\u2019s syndrome","volume":"72","author":"Pollard","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1590\/1807-3107bor-2017.vol31.0008","article-title":"Effects of periodontal treatment on primary sjogren\u2019s syndrome symptoms","volume":"31","author":"Ambrosio","year":"2017","journal-title":"Braz. Oral Res."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/jcpe.12485","article-title":"Periodontitis prevalence and serum antibody reactivity to periodontal bacteria in primary Sjogren\u2019s syndrome: A pilot study","volume":"43","author":"Lugonja","year":"2016","journal-title":"J. Clin. Periodontol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.oooo.2017.11.018","article-title":"Relationship between sjogren syndrome and periodontal status: A systematic review","volume":"125","author":"Rocha","year":"2018","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.clim.2016.04.010","article-title":"T cells and IL-17 in lupus nephritis","volume":"185","author":"Koga","year":"2017","journal-title":"Clin. Immunol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/cei.12905","article-title":"RORgammat expression in Tregs promotes systemic lupus erythematosus via IL-17 secretion, alteration of Treg phenotype and suppression of Th2 responses","volume":"188","author":"Kluger","year":"2017","journal-title":"Clin. Exp. Immunol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.molmed.2017.05.006","article-title":"Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective","volume":"23","author":"Moulton","year":"2017","journal-title":"Trends Mol. Med."},{"key":"ref_164","first-page":"208","article-title":"Immunological signatures in saliva of systemic lupus erythematosus patients: Influence of periodontal condition","volume":"37","author":"Mendonca","year":"2019","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Wu, Y.D., Lin, C.H., Chao, W.C., Liao, T.L., Chen, D.Y., and Chen, H.H. (2017). Association between a history of periodontitis and the risk of systemic lupus erythematosus in Taiwan: A nationwide, population-based, case-control study. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0187075"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s10067-013-2473-2","article-title":"Periodontitis treatment improves systemic lupus erythematosus response to immunosuppressive therapy","volume":"33","author":"Fabbri","year":"2014","journal-title":"Clin. Rheumatol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/nature08933","article-title":"Genetics, pathogenesis and clinical interventions in type 1 diabetes","volume":"464","author":"Bluestone","year":"2010","journal-title":"Nature"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"666","DOI":"10.7150\/ijbs.6610","article-title":"Risk factors and primary prevention trials for type 1 diabetes","volume":"9","author":"Wu","year":"2013","journal-title":"Int. J. Biol. Sci."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.2337\/db08-1113","article-title":"Inhibition of Th17 cells regulates autoimmune diabetes in NOD mice","volume":"58","author":"Emamaullee","year":"2009","journal-title":"Diabetes"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.4049\/jimmunol.1000788","article-title":"IL-17 immunity in human type 1 diabetes","volume":"185","author":"Honkanen","year":"2010","journal-title":"J. Immunol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/gene.2016.44","article-title":"Pre-diagnostic genotyping identifies T1D subjects with impaired Treg IL-2 signaling and an elevated proportion of FOXP3(+)IL-17(+) cells","volume":"18","author":"Marwaha","year":"2017","journal-title":"Genes Immun."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"379626","DOI":"10.1155\/2015\/379626","article-title":"Periodontal Diseases and Dental Caries in Children with Type 1 Diabetes Mellitus","volume":"2015","author":"Novotna","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00125-011-2342-y","article-title":"Periodontitis and diabetes: A two-way relationship","volume":"55","author":"Preshaw","year":"2012","journal-title":"Diabetologia"},{"key":"ref_174","first-page":"Cd004714","article-title":"Treatment of periodontal disease for glycaemic control in people with diabetes mellitus","volume":"11","author":"Simpson","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"e5516","DOI":"10.1097\/MD.0000000000005516","article-title":"Cytotoxic Th1 and Th17 cells infiltrate the intestinal mucosa of Behcet patients and exhibit high levels of TNF-alpha in early phases of the disease","volume":"95","author":"Emmi","year":"2016","journal-title":"Medicine"},{"key":"ref_176","first-page":"14","article-title":"Th17 cells and IL-17 promote the skin and lung inflammation and fibrosis process in a bleomycin-induced murine model of systemic sclerosis","volume":"34","author":"Lei","year":"2016","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/cei.12670","article-title":"The interleukin (IL)-23\/IL-17 axis in ankylosing spondylitis: New advances and potentials for treatment","volume":"183","author":"Jethwa","year":"2016","journal-title":"Clin. Exp. Immunol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.msard.2017.09.003","article-title":"Levels of peripheral Th17 cells and serum Th17-related cytokines in patients with multiple sclerosis: A meta-analysis","volume":"18","author":"Li","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/ene.12520","article-title":"No association between multiple sclerosis and periodontitis after adjusting for smoking habits","volume":"22","author":"Gustavsen","year":"2015","journal-title":"Eur. J. Neurol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/ene.12103","article-title":"Association between multiple sclerosis and chronic periodontitis: A population-based pilot study","volume":"20","author":"Sheu","year":"2013","journal-title":"Eur. J. Neurol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1007\/s10067-017-3861-9","article-title":"Risk association between scleroderma disease characteristics, periodontitis, and tooth loss","volume":"36","author":"Isola","year":"2017","journal-title":"Clin. Rheumatol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"7506041","DOI":"10.1155\/2016\/7506041","article-title":"Periodontal health status among patients with Behcet\u2019s Disease","volume":"2016","author":"Habibagahi","year":"2016","journal-title":"Scientifica"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3892\/br.2012.42","article-title":"TNF inhibitor therapy for rheumatoid arthritis","volume":"1","author":"Ma","year":"2013","journal-title":"Biomed. Rep."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/nrrheum.2017.187","article-title":"Immunogenicity and loss of response to TNF inhibitors: Implications for rheumatoid arthritis treatment","volume":"13","author":"Kalden","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-540-73259-4_1","article-title":"Historical development of monoclonal antibody therapeutics","volume":"181","author":"Nissim","year":"2008","journal-title":"Handb. Exp. Pharmacol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(00)01034-5","article-title":"Therapeutic monoclonal antibodies","volume":"355","author":"Breedveld","year":"2000","journal-title":"Lancet"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/ecco-jcc\/jjw053","article-title":"Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease","volume":"10","author":"Levin","year":"2016","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_188","doi-asserted-by":"crossref","unstructured":"Yost, J., and Gudjonsson, J.E. (2009). The role of TNF inhibitors in psoriasis therapy: New implications for associated comorbidities. F1000 Med. Rep., 1.","DOI":"10.3410\/M1-30"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/sj.bjp.0706979","article-title":"Effects of etanercept, a tumour necrosis factor-alpha antagonist, in an experimental model of periodontitis in rats","volume":"150","author":"Mazzon","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.3389\/fimmu.2018.02746","article-title":"Psoriasis: Classical vs. Paradoxical. The Yin-Yang of TNF and Type I Interferon","volume":"9","author":"Mylonas","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jaad.2016.08.012","article-title":"Tumor necrosis factor-alpha inhibitor-induced psoriasis: Systematic review of clinical features, histopathological findings, and management experience","volume":"76","author":"Brown","year":"2017","journal-title":"J. Am. Acad. Derm."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s40257-017-0296-7","article-title":"Clinical Signs, Pathophysiology and Management of Cutaneous Side Effects of Anti-Tumor Necrosis Factor Agents","volume":"18","author":"Segaert","year":"2017","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/art.40070","article-title":"Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double-Blind, Active Comparator- and Placebo-Controlled Study","volume":"69","author":"Blanco","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/RHU.0000000000000041","article-title":"Periodontitis and etanercept discontinuation risk in anti-tumor necrosis factor-naive rheumatoid arthritis patients: A nationwide population-based cohort study","volume":"19","author":"Chen","year":"2013","journal-title":"J. Clin. Rheumatol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/eji.200839088","article-title":"Diseases that may benefit from manipulating the Th17 pathway","volume":"39","author":"Miossec","year":"2009","journal-title":"Eur. J. Immunol."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1136\/annrheumdis-2011-201024","article-title":"Incomplete response of inflammatory arthritis to TNFalpha blockade is associated with the Th17 pathway","volume":"71","author":"Alzabin","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/14712598.2019.1579794","article-title":"Brodalumab for the treatment of plaque psoriasis: Up-to-date","volume":"19","author":"Beck","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1136\/annrheumdis-2012-201601","article-title":"Efficacy and safety of secukinumab in patients with rheumatoid arthritis: A phase II, dose-finding, double-blind, randomised, placebo controlled study","volume":"72","author":"Genovese","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3899\/jrheum.140831","article-title":"Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid Arthritis","volume":"43","author":"Genovese","year":"2016","journal-title":"J. Rheumatol."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1056\/NEJMoa1109997","article-title":"Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis","volume":"366","author":"Leonardi","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"52ra72","DOI":"10.1126\/scitranslmed.3001107","article-title":"Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis","volume":"2","author":"Hueber","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1177\/1060028018799982","article-title":"Ixekizumab: A Review of Its Use for the Management of Moderate to Severe Plaque Psoriasis","volume":"53","author":"Shelton","year":"2019","journal-title":"Ann. Pharmacother."},{"key":"ref_203","doi-asserted-by":"crossref","unstructured":"Blauvelt, A., Lomaga, M., Burge, R., Zhu, B., Shen, W., Shrom, D., Dossenbach, M., and Pinter, A. (2019). Greater Cumulative Benefits from Ixekizumab versus Ustekinumab Treatment over 52 Weeks for Patients with Moderate-to-Severe Psoriasis in a Randomized, Double-Blinded Phase 3b Clinical Trial. J. Dermatol. Treat., 1\u201321.","DOI":"10.1080\/09546634.2019.1587146"},{"key":"ref_204","doi-asserted-by":"crossref","unstructured":"Amin, M., Darji, K., No, D.J., Bhutani, T., and Wu, J.J. (2017). Review of IL-17 inhibitors for psoriasis. J. Dermatol. Treat., 1\u20136.","DOI":"10.1080\/09546634.2017.1395796"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1080\/09546634.2017.1422591","article-title":"A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12\/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis","volume":"29","author":"Bilal","year":"2018","journal-title":"J. Dermatol. Treat."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s00296-016-3480-9","article-title":"Anti-IL-17 therapy in treatment of rheumatoid arthritis: A systematic literature review and meta-analysis of randomized controlled trials","volume":"36","author":"Kunwar","year":"2016","journal-title":"Rheumatol. Int."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1186\/s13075-014-0426-z","article-title":"Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: Possible explanation for nonresponse to anti-IL-17 therapy?","volume":"16","author":"Lebre","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s40264-019-00797-3","article-title":"Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn\u2019s Disease: An Integrated Analysis of Phase II\/III Clinical Development Programs","volume":"42","author":"Ghosh","year":"2019","journal-title":"Drug Saf."},{"key":"ref_212","unstructured":"(2009). Ustekinumab: New drug. Suspicion of carcinogenicity: Too great a risk for psoriasis patients. Prescrire Int., 18, 202\u2013204."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1056\/NEJMoa1612197","article-title":"Interleukin-12 and Interleukin-23 Blockade in Leukocyte Adhesion Deficiency Type 1","volume":"376","author":"Moutsopoulos","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_214","first-page":"119","article-title":"Guselkumab for the Treatment of Psoriasis","volume":"32","author":"Machado","year":"2018","journal-title":"Biodrugs Clin. Immunother. Biopharm. Gene Ther."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1177\/1060028018809522","article-title":"Tildrakizumab: A Review of Phase II and III Clinical Trials","volume":"53","author":"Kolli","year":"2019","journal-title":"Ann. Pharmacother."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/14\/3394\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:04:24Z","timestamp":1760187864000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/14\/3394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,10]]},"references-count":215,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2019,7]]}},"alternative-id":["ijms20143394"],"URL":"https:\/\/doi.org\/10.3390\/ijms20143394","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,10]]}}}